



GP1652

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/818,990	
	<b>Filing Date</b>	Mar 27, 2001	
	<b>First Named Inventor</b>	Walke, D. Wade	
	<b>Group Art Unit</b>	1652	
	<b>Examiner Name</b>	S. Swope	
<b>Total Number of Pages in This Submission</b>	57	<b>Attorney Docket Number</b>	LEX-0152-USA

RECEIVED  
APR 03 2003  
TECH CENTER 1600/2900**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	- Return Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	- Exhibits A - F
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<b>Remarks</b>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

<b>Firm or Individual name</b>	Lexicon Genetics Incorporated Lance K. Ishimoto Reg. No. 41,866	
<b>Signature</b>	Lance K. Ishimoto by David W. Hoyer DAVID W. HOYER REG. NO. 41,071	24231 PATENT TRADEMARK OFFICE
<b>Date</b>	March 26, 2003	

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Arlington, VA 22202 on this date: <u>March 26, 2003</u>			
<b>Typed or printed name</b>	Michelle Klein		
<b>Signature</b>	Michelle Klein	<b>Date</b>	March 26, 2003



# 19/B  
DmJ  
4-2-03  
**RECEIVED**

APR 03 2003

TECH CENTER 1600/2900

Applicant(s): Walke *et al.* Group Art Unit: 1652  
Application No.: 09/818,990 Examiner: S. Swope  
Filed: 3/27/2001  
Atty. Docket No.: LEX-0152-USA  
Title: Novel Human Muscle Proteins and  
Polynucleotides Encoding the Same (As Amended)

**AMENDMENT AND RESPONSE TO OFFICE ACTION**  
**DATED DECEMBER 27, 2002**

Assistant Commissioner for Patents  
Arlington, VA 22202

Sir:

Applicants acknowledge the receipt of the Office Action ("the Action") mailed on December 27, 2002 (Paper No. 18), which has been carefully reviewed and studied. The Examiner is respectfully requested to enter the following amendments. Reexamination and reconsideration of the application is requested in view of the following amendments and remarks. In order to facilitate the Examiner's evaluation of the application, Applicants have attempted to address the objections and rejections in Paper No. 18 in the same order in which they were originally raised.

The response is timely filed. Applicants believe no fees are due in connection with this response. However, the Commissioner is authorized to charge any required fees or credit any overpayment to Deposit Account No. 50-0892.

**AMENDMENT**

**In the specification:**

Please delete the present title and replace with the new title--Human Ion Channel Proteins  
and Polynucleotides Encoding the Same--.

